Evotec and Apeiron Biologics build Pain Alliance
Evotec will apply, in a first instance, its expertise in cellular assay development with opportunities for the project to rapidly move into hit identification and beyond.
Dr Hans Loibner, Chief Executive Officer at Apeiron Biologics, commented: "Combining our two companies' skills is an excellent way to move forward with this innovative and promising project. We have worked with Evotec in the past and continue to be impressed by the quality of the work performed there."
Dr Werner Lanthaler, Chief Executive Officer at Evotec stated: "Apeiron is certainly one of the most exciting young biotech companies in Europe. We are happy that through the optimal use of R&D outsourcing Evotec can add value here."
No financial details are disclosed.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.